Israeli hospital claims new drug ‘cured’ 29 of 30 moderate to severe Covid patients in days
A medicine that was being developed for cancer has shown potential in modulating the immune response to prevent the deadly cytokine storm. Researchers call it a breakthrough as 29 of 30 phase 1 trial patients left hospital within 3-5 days.
Tel Aviv’s Ichilov Medical Center has successfully completed the phase 1 trials for a new drug that appears to have helped numerous moderate-to-serious cases to quickly recover from COVID-19. The hospital calls it a huge breakthrough as all 30 patients suffering from moderate to severe Covid-19, who received the drug recovered — 29 of them within three to five days.
EXO-CD24 -a targeted drug that was being developed as a cure for cancer for the past few years, makes use of tiny carrier sacs knows as exosomes to deliver a protein called CD24 to the lungs. The drug fights the cytokine storm, which is an overreaction to the SARS-CoV-2 infection by the immune system that is believed to be potentially lethal.
The drug EXO-CD24 is different from other molecules in that it is directly inhaled into the lungs, which happen to be the epicentres of the cytokine storm. It is to be inhaled once a day for a few minutes, for five days.